Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 2, 2013, Pages 537-541

  Melguizo, Consolación ^a   Prados, Jose ^a,d   Luque, Raquel ^b   Ortiz, Raúl ^c   Rama, Ana R ^c   Caba, Octavio ^c   Rodríguez Serrano, Fernando ^a   Álvarez, Pablo J ^a   Aránega, Antonia ^a  

^a Institute of Biopathology and Regenerative Medicine IBIMER   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

^d UNIVERSITY OF GRANADA   (Spain)

Author keywords

Carboplatin; Drug resistance; LRP; Lung cancer; MDR1; MRP3; Paclitaxel; Prognosis

Indexed keywords

CARBOPLATIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; LRP GENE; LUNG NON SMALL CELL CANCER; MALE; MRP3 GENE; MULTIDRUG RESISTANCE 1 GENE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM STAGING; P-GLYCOPROTEIN; PACLITAXEL; SURVIVAL RATE; TREATMENT OUTCOME; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 84874107231     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2036-2     Document Type: Article

References (19)

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584-594
2. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE (2012) Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 15:50-61
3. Hilgeroth A, Hemmer M, Coburger C (2012) The impact of the induction of multidrug resistance transporters in therapies by used drugs: recent studies. Mini Rev Med Chem [Epub ahead of print]
4. Kamazawa S, Kigawa J, Minagawa Y, Itamochi H, Shimada M, Takahashi M, Sato S, Akeshima R, Terakawa N (2000) Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells. Oncology 59:329-335
5. Laurençot CM, Scheffer GL, Scheper RJ, Shoemaker RH (1997) Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int J Cancer 72:1021-1026
6. Berger W, Elbling L, Hauptmann E, Micksche M (1997) Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer 73:84-93
7. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH (2001) Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7:1798-1804
8. Wang M, Hong X, Sun Q, Li R, Yang Z, Chen G (2012) Establishment of animal model of a human lung adenocarcinoma drug-resistant cell line Anip973/NVB and investigation on mechanism of drug resistance. Zhongguo Fei Ai Za Zhi 15:146-151
9. Chen ZJ, Le HB, Zhang YK, Qian LY, Sekhar KR, Li WD (2011) Lung resistance protein and multidrug resistance protein in non-small cell lung cancer and their clinical significance. J Int Med Res 39:1693-1700
10. Oguri T, Isobe T, Fujitaka K, Ishikawa N, Kohno N (2001) Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer. Int J Cancer 93:584-589
11. Thatcher N, Heighway J (2010) Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer. Oncologist 15:1034-1042
12. Chiou JF, Liang JA, Hsu WH, Wang JJ, Ho ST, Kao A (2003) Comparing the relationship of taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung 181:267-273
13. Bogush TA, Konukhova AV, Ravcheeva AB, Zabotina TN, Kadagidze ZG, Bogush EA et al (2003) Inhibition of ABC-transporter(s)' function in non-small cell lung cancer cells by platinum drugs. Antibiot Khimioter 48:11-15
14. Berger W, Elbling L, Micksche M (2000) Expression of the major vault protein LRP in human nonsmall-cell lung cancer cells: activation by shortterm exposure to antineoplastic drugs. Int J Cancer 88:293-300
15. Rolff J, Dorn C, Merk J, Fichtner I (2009) Response of patient-derived non-small cell lung cancer xenografts to classical and targeted therapies is not related to multidrug resistance markers. J Oncol 2009:814140
16. Volm M, Koomägi R, Mattern J, Efferth T (2002) Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer 87:251-257
17. Li X-Q, Li J, Chen P (2008) Expression and clinical significance of MRP1 and LRP mRNA in non small cell lung cancer. Pract J Cancer 23:145-147
18. Baik SH, Jee BK, Choi JS, Yoon HK, Lee KH, Kim YH et al (2009) DNA profiling by array comparative genomic hybridization (CGH) of peripheral blood mononuclear cells (PBMC) and tumor tissue cell in non-small cell lung cancer (NSCLC). Mol Biol Rep 36:1767-1778
19. Oguri T, Fujiwara Y, Isobe T, Katoh O, Watanabe H, Yamakido M (1998) Expression of gamma-glutamylcysteine synthetase (gamma-CGS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs. Br J Cancer 77:1089-1096